JP4683920B2 - Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 - Google Patents

Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 Download PDF

Info

Publication number
JP4683920B2
JP4683920B2 JP2004515703A JP2004515703A JP4683920B2 JP 4683920 B2 JP4683920 B2 JP 4683920B2 JP 2004515703 A JP2004515703 A JP 2004515703A JP 2004515703 A JP2004515703 A JP 2004515703A JP 4683920 B2 JP4683920 B2 JP 4683920B2
Authority
JP
Japan
Prior art keywords
fluoropyridin
benzonitrile
treatment
metabotropic glutamate
glutamate receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004515703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006507225A5 (enExample
JP2006507225A (ja
Inventor
リーマン，アンダーズ
マットソン，ジャン
トーマス，エム．ストーマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4683920(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2006507225A publication Critical patent/JP2006507225A/ja
Publication of JP2006507225A5 publication Critical patent/JP2006507225A5/ja
Application granted granted Critical
Publication of JP4683920B2 publication Critical patent/JP4683920B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2004515703A 2002-06-20 2003-06-19 Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 Expired - Fee Related JP4683920B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use
PCT/US2003/016223 WO2004000316A1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010268162A Division JP2011068669A (ja) 2002-06-20 2010-12-01 Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用

Publications (3)

Publication Number Publication Date
JP2006507225A JP2006507225A (ja) 2006-03-02
JP2006507225A5 JP2006507225A5 (enExample) 2006-07-20
JP4683920B2 true JP4683920B2 (ja) 2011-05-18

Family

ID=20288301

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004515703A Expired - Fee Related JP4683920B2 (ja) 2002-06-20 2003-06-19 Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用
JP2010268162A Pending JP2011068669A (ja) 2002-06-20 2010-12-01 Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010268162A Pending JP2011068669A (ja) 2002-06-20 2010-12-01 Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用

Country Status (24)

Country Link
EP (1) EP1513525B1 (enExample)
JP (2) JP4683920B2 (enExample)
CN (1) CN100430056C (enExample)
AT (1) ATE395059T1 (enExample)
AU (1) AU2003241585B2 (enExample)
BR (1) BR0311759A (enExample)
CA (1) CA2489730C (enExample)
CY (1) CY1107954T1 (enExample)
DE (1) DE60320990D1 (enExample)
DK (1) DK1513525T3 (enExample)
ES (1) ES2304510T3 (enExample)
IL (1) IL165138A0 (enExample)
IS (1) IS7654A (enExample)
MX (1) MXPA04012659A (enExample)
NO (1) NO20050154L (enExample)
NZ (1) NZ536559A (enExample)
PL (1) PL372186A1 (enExample)
PT (1) PT1513525E (enExample)
RU (1) RU2324484C2 (enExample)
SE (1) SE0201943D0 (enExample)
SI (1) SI1513525T1 (enExample)
UA (1) UA81627C2 (enExample)
WO (1) WO2004000316A1 (enExample)
ZA (1) ZA200409908B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
CN1918154A (zh) * 2004-02-18 2007-02-21 阿斯利康(瑞典)有限公司 多杂环化合物及其作为代谢型谷氨酸受体拮抗剂的用途
RU2006128445A (ru) * 2004-02-18 2008-03-27 Астразенека Аб (Se) Ацетилиновые пиперазиновые соединения и их применение в качестве антагонистов метаботропных глутаматных рецепторов
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
SI2001849T1 (sl) * 2006-03-29 2015-02-27 F. Hoffmann-La Roche Ag Derivati piridina in pirimidina kot antagonisti mglur2
KR20090061041A (ko) 2006-09-11 2009-06-15 노파르티스 아게 대사성 글루타메이트 수용체의 조절제로서의 니코틴산 유도체
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
EP2826478A1 (en) 2008-06-30 2015-01-21 Novartis AG Combinations comprising mglur modulators for the treatment of parkinson's disease
WO2011009890A2 (en) 2009-07-23 2011-01-27 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
EP2490691A1 (en) 2009-10-20 2012-08-29 Novartis AG Use of 1h-quinazoline-2,4-diones
RU2013103001A (ru) 2010-06-24 2014-07-27 Новартис Аг Применение 1н-хиназолин-2,4-дионов
US20140171448A1 (en) 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2013036224A1 (en) 2011-09-07 2013-03-14 Novartis Ag Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
BR112015016994A8 (pt) 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
US20220387410A1 (en) * 2019-11-05 2022-12-08 Claes Thulin 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594424B2 (en) * 1986-01-03 1990-03-08 University Of Melbourne, The Gastro-oesophageal reflux composition
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
JP2002515448A (ja) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン 食道逆流病の処置法
RU2144331C1 (ru) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Способ лечения хронического гиперпластического ларингита
CZ2002599A3 (cs) * 1999-08-19 2002-06-12 Nps Pharmaceuticals Inc. Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu
US7115630B2 (en) * 2000-10-02 2006-10-03 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists

Also Published As

Publication number Publication date
SI1513525T1 (sl) 2008-08-31
AU2003241585B2 (en) 2009-06-25
ZA200409908B (en) 2006-08-30
NO20050154L (no) 2005-01-11
SE0201943D0 (sv) 2002-06-20
MXPA04012659A (es) 2006-05-25
AU2003241585A1 (en) 2004-01-06
PL372186A1 (en) 2005-07-11
BR0311759A (pt) 2005-03-08
ES2304510T3 (es) 2008-10-16
PT1513525E (pt) 2008-06-24
DK1513525T3 (da) 2008-08-11
CN1662235A (zh) 2005-08-31
HK1075833A1 (en) 2005-12-30
RU2005101411A (ru) 2005-07-10
EP1513525A1 (en) 2005-03-16
JP2006507225A (ja) 2006-03-02
IS7654A (is) 2005-01-19
UA81627C2 (ru) 2008-01-25
CN100430056C (zh) 2008-11-05
CA2489730C (en) 2011-11-22
CY1107954T1 (el) 2013-09-04
IL165138A0 (en) 2005-12-18
RU2324484C2 (ru) 2008-05-20
WO2004000316A1 (en) 2003-12-31
DE60320990D1 (de) 2008-06-26
ATE395059T1 (de) 2008-05-15
JP2011068669A (ja) 2011-04-07
CA2489730A1 (en) 2003-12-31
NZ536559A (en) 2007-08-31
EP1513525B1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
JP4683920B2 (ja) Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用
US11413258B2 (en) Methods for treating cancer
KR100568659B1 (ko) 역류 억제제
KR20180127493A (ko) 승모판 질환으로 인한 무증상 심부전이 있는 환자에서 심장 크기의 감소 및/또는 임상적 증상 개시의 지연을 위한 피모벤단의 용도
US6040324A (en) Prophylactic or therapeutic drug for renal diseases
JP2014511365A5 (enExample)
JP6509729B2 (ja) 慢性腎臓病の進行抑制又は改善剤
EP2568982B1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
US7964609B2 (en) Use of mGluR5 antagonists for the treatment of gerd
AU2002328569B2 (en) Medicinal compositions containing angiotensin II receptor antagonist
KR20050024351A (ko) Ｇｅｒｄ 치료용 ｍｇｌｕｒ５ 길항제의 용도
HK1075833B (en) Use of mglur5 antagonists for the treatment of gerd
WO2016092060A1 (en) Veterinary composition comprising torasemide for the treatment of pulmonary edema associated with heart failure in domestic animals
WO2005058361A1 (en) USE OF mGluR1 ANTAGONISTS FOR THE TREATMENT OF GERD
WO2006046746A1 (ja) 内臓痛予防・治療剤
WO2005058326A1 (en) USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs)
WO2024204277A1 (ja) 成長ホルモン分泌促進剤
JP2007514741A (ja) 消化管障害の治療のための代謝調節型グルタミン酸受容体５（ｍＧＬｕＲ５）拮抗剤の使用
AU9703601A (en) Method for treating chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060531

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110208

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140218

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees